Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1649094 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $52.98Day −2.97%Mkt cap $7.7B1Y +52.8%Off 52W high −18.5%Vol (1Y) 46.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.9% of sh out |
| Days to cover12.4d |
| 13F net flow (QoQ)+2.93% |
| Top-10 13F concentration58.4% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$946.5M |
| ROE−25.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+14.8% |
| 1Y+52.8% |
| 3Y+10.2% |
| 5Y+131.2% |
| Since incept. (ann.)+14.0% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)46.7% |
| Ann. volatility (3Y)57.9% |
| Sharpe (1Y)1.09 |
| Sharpe (3Y)0.38 |
| Max drawdown (1Y)−26.5% |
| Max drawdown (3Y)−76.2% |
| Beta (3Y vs SPY)1.34 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 16.6M | $960M | 11.48% | +23.8% |
| FMR LLC | 16.5M | $958M | 11.42% | +19.2% |
| T. Rowe Price Investment Management, Inc. | 12.1M | $705M | 8.40% | −32.6% |
| RA CAPITAL MANAGEMENT, L.P. | 11.5M | $667M | 7.95% | +7.0% |
| BlackRock, Inc. | 11.0M | $638M | 7.60% | +7.1% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.3M | $365M | 4.35% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.3M | $364M | 4.34% | new |
| WELLINGTON MANAGEMENT GROUP LLP | 5.6M | $326M | 3.89% | −5.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 112.6% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 14,143,473 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$2.30 | — | — | — |
| 2025-09-30 | 2025-11-04 | −$1.56 | — | — | — |
| 2025-06-30 | 2025-08-06 | −$1.22 | — | — | — |
| 2025-03-31 | 2025-05-07 | −$1.04 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
